A little GC, like a glass of wine, may benefit many people, whereas a high dose of GC, like a bottle of wine, is harmful to all.

**MECHANISMS, USE, AND DOSAGES**

To better understand published reports on the effects of GCs in RA, it is important to recognize two different aspects of the disease process. The first aspect is clinical symptoms of inflammation. This process is partly due to infiltration of the synovial tissue by lymphocytes. The second aspect is erosive progression of the disease, which can be inhibited by disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and tumour necrosis factor α blockers. This process is partly due to synovial infiltration by macrophages. Both processes are closely linked, but partially independent and both processes may respond differently to different interventions. GCs seem to influence the inflammatory process especially during the first months of treatment, while effects on erosions become evident after a more prolonged period of time.

“Glucocorticoids act on the inflammatory process immediately and on erosions only after a longer period of time”

GCs have a profound effect on the immune system, interfering with the cytokine network and inflammatory enzymes, and with adhesion molecules, permeability factors, cellular function, and survival. GCs are still the most effective anti-phlogistic and immune suppressive substances known. In early RA, and even in some patients before they develop RA, an insufficiency of the hypothalamic pituitary adrenal (HPA) axis has been documented. Discussion is still continuing as to whether or not this is the “chicken or the egg”. In any case it is evident from many studies that cortisol levels found in patients with RA are insufficient to control the continuing inflammatory process.

In America up to 75% of patients with RA use glucocorticoids regularly, concomitantly with other drugs. In Europe the percentage is around 25%, although the role of GCs was reassessed in Europe during the past decade. In the third world, GC use is very common, as they are one of the only cheap and widely available drugs; they are often sold over the counter. The official views (as expressed in textbooks on both sides of the Atlantic) are similar and consistent in their opposition to GC treatment. The 2002 update of the guidelines for the management of rheumatoid arthritis of the ACR states: “Low dose oral glucocorticoids (10 mg or less of prednisone daily) are highly effective at relieving symptoms in patients with active RA. A patient disabled by active polyarthritis may experience marked and rapid improvement in functional status within days following initiation of glucocorticoids. Frequently, disabling synovitis recurs when glucocorticoids are discontinued, even in patients who are receiving combination therapy with one or more DMARDs. Therefore, many patients with RA are functionally dependent on glucocorticoids and continue them long term.”

What is considered to be a low dose of GCs? In patients with active RA participating in most clinical trials, a mean dosage of glucocorticoids of the order of 7 mg/day is found. In descriptive cohort studies of patients with long-standing RA many patients have less active disease and the mean dosage of glucocorticoids is of the order of 3–5 mg/day, implying that some patients do very well on even a very low dose of GCs. Recently, a consensus meeting on standardisation of the nomenclature of GCs in rheumatic diseases was held. In the meeting report definitions for the dosage, based on pathophysiological and pharmacokinetic data, were suggested: “low dose” was defined as 7.5 mg or less prednisone equivalent a day, a “medium dose” as 7.5–30 mg daily, and a “high dose” was defined as above 30 mg daily.

**DOGMA AND FACTS: EFFICACY**

**Clinical signs of inflammation**

It is astonishing to note the paucity of published data that can stand up to critical assessment by current standards. In 1997, a Cochrane review concluded on the basis of seven studies and a total of 253 patients: “Although our findings are based on very few controlled studies, they generally uphold the widely held belief that corticosteroids, when administered for periods of approximately 6 months, are effective for the treatment of RA.” This conclusion supports the widespread use of GCs, even though guidelines are more negative.
More recent trials and follow up studies have added important data to our still limited understanding. One hundred and one patients with established RA co-treated with conventional DMARDs were included in a placebo controlled trial that studied 30 mg prednisone daily tapered to 7.5 mg in three weeks, and further tapered according to clinical activity.14 More rapid onset of effect in the GC group was found, but the difference between treatment groups was lost after a few months, although effects on Lequesne Assessment Questionnaire (HAQ) and grip strength persisted. The Utrecth group performed a placebo controlled trial of 10 mg prednisone as monotherapy in early (<1 year), DMARD naive patients (total, n = 81).14 The duration of the trial was two years; rescue sulfasalazine was allowed after six months, and more than half of the patients in each group started this drug.

“Cochrane review supports the use of GCs, though guidelines are more negative”

At six months, improvement in disease activity was more rapid in the GC group, despite lower use of intra-articular injections and NSAIDs. However, these differences were no longer significant at one year and later, though the use of NSAIDs and intra-articular injections stayed lower in the GC group. Together with very similar results from the UK,14 one can conclude that low to medium dose prednisolone (up to 10 mg/day) added to other DMARDS leads to rapid clinical response that in general does not persist beyond six months.

Radiographic damage

From the late 1950s onwards studies have pointed to an effect on radiographic damage. Although the early studies were well designed, the results are not so easily summarised because scoring was not standardised. A Cochrane review is currently underway; it will include over 700 patients in about 10 studies.12–14 The overwhelming signal is that GCs retard radiological progression. One of the studies included is the COBRA trial,15 for which data on long term follow up were recently published.16 This trial compared the combination of step-down prednisolone (60 mg/day down to 7.5 mg/day in seven weeks), methotrexate, and sulfasalazine with sulfasalazine alone: clinical benefits were no longer significant after GCs were stopped, but differences in damage progression were evident up to one year after stopping GCs. It must be emphasised that this was a trial with an active treatment control group and that the patients in this group responded adequately to sulfasalazine as expected. In the long term follow up of COBRA (mean 4.5 years) the yearly rate of progression remained significantly and relevantly lower in the combination group (5.4 Sharp points per year × 8.6 in the sulfasalazine group) despite equal treatment, disease activity, and HAQ in both groups. The fact that the progression lines are not parallel (suggesting the initial advantage is maintained) but actually diverge suggests true disease modification of the combination schedule, with GCs in this dose acting either as a specific disease modifier, or as the agent working generically by inducing the rapid initial suppression of disease activity. In the Utrecth study, the only recent study in which GCs were used as monotherapy, a significant decrease in radiographic progression was also seen in the patients, starting at six months.15 Comparable data were reported in the UK study in patients with RA in whom GCs were added to other antiinflammatory treatment.14 In conclusion, low dose GCs clearly decrease radiological progression.

Efficacy summary

GCs are still the most effective antiinflammatory and immune suppressive substances known. When given for periods of about six months, GCs are effective in reducing signs and symptoms of inflammation in RA; after that time the symptomatic effect wanes when GCs are used as co-medication with DMARDS, though co-medication of NSAIDs, use of intra-articular injections, and other treatments are lower when GCs are continued. Apart from this symptomatic effect it has now become clear that GCs can reduce the progression of erosions in patients with RA, an effect that even seems to persist when GC treatment is stopped.

DOGMA AND FACTS: TOXICITY

There is no question that GCs, especially in high doses and continued for longer periods, can cause devastating morbidity. Although the textbooks are full of the “well known” side effects of GCs, we actually know little of their incidence, prevalence, and true impact; and almost nothing about the relation of these effects with different dosing schedules. The quality of evidence on toxicity is even less than that for efficacy. Table 1 lists the toxicities typically associated with chronic GC use. Potential side effects can be divided into those that are possibly preventable and ones that are largely idiosyncratic and typically not preventable. Although observational studies of serious GC adverse effects (AEs) identify fractures and ocular toxicity as among the most prevalent,17 patients often worry more about less serious, albeit more apparent, sequelae such as cushingoid facies, skin thinning, and ecchymoses. Catabolic effects on the skin during systemic GC treatment include cutaneous atrophy, resulting from GC effects on keratinocytes and fibroblasts. Decreased vascular structural integrity is probably a key determinant of purpura and easy bruisability in GC treated patients.18 These effects were reported to affect over 5% of those exposed to 5 mg or more prednisone equivalent for one year or longer.19 At the lower dose range of GCs (below the physiological threshold) commonly used by American doctors to manage RA, change in personal appearance is an uncommon outcome. However, the traditionally assumed physiological threshold (about 7.5 mg/day of prednisone) may be overestimated20; thus, even very low doses may exceed it and lead to these AEs.

Bone

Of all serious AEs attributed to GCs, bone loss leading to fractures provokes the most trepidation among knowledgeable doctors. Long term follow up of women in the large Arthritis and Medical Information System (ARAMIS) cohort identified a risk of about 33% of having a fracture after five years of follow up on an average GC dose of only 8.6 mg/day.21 In a large Norwegian cohort current GC use was associated with loss of bone mineral density (BMD) at both the total hip (adjusted odds ratio (aOR) = 2.6) and spine (aOR = 2.7).22 Although factors other than BMD predispose to fracture risk in these patients, BMD of both the spine and hip is a significant independent predictor of vertebral fracture among GC users.23 Negative effects on bone formation, in contrast with heightened bone resorption, appear to be most central to GC induced osteoporosis.24

“Some data suggest that GCs may even benefit the bones of patients with RA”

Despite this pathogenic rationale and accumulating evidence from observational studies on GC risk to bone, some data suggest that GCs may actually benefit bones in patients with RA.25 This benefit may be brought about by decreasing the disease activity, promoting beneficial weightbearing activity and a reduction in proinflammatory cytokines deleterious to bone.26 These dissenting opinions on the toxicity of
Glucocorticoids to bone have been strengthened by mixed and inconclusive results from recent large randomised controlled trials (RCTs) of GC use in RA. It is important to note, however, that to date GC RCTs have been significantly underpowered to detect even modest differences in fractures between patients receiving and not receiving GCs. In addition to doctors’ concerns and beyond the disability, morbidity, and attributable mortality of fractures, patients receiving GCs greatly fear this complication. When the preferences of a patient with RA for GC sequelae were evaluated using hypothetical decision scenarios, serious fractures were rated as the worst of all possible GC complications (preference value of 0.55; values are anchored at 0 = death and 1 = current health). Although the osteoporosis complications of GC use are a major reason for questioning their role in RA management, the advent of effective and safe prevention for GC induced osteoporosis has partially ameliorated this problem. The ACR and a number of other specialty based consensus groups have issued guidelines or position statements advocating a much more aggressive approach to GC induced osteoporosis prevention.

In addition to periodic bone mass measurement, American, Canadian, and Australian guidelines also advocate the aggressive use of aminobisphosphonate drugs such as alendronate or risedronate. Although the indications for the use of bisphosphonate vary based on these different guidelines, patients expected to require prolonged supra-physiological GC doses, those with existing low bone mass (T score < −1.0 in some and less than −1.5 in other guidelines), and postmenopausal women are high risk groups that should receive bisphosphonates sooner rather than later. Other therapeutic options such as calcitonin, oestrogen, testosterone, and possibly, thiazide diuretics (early in the course of GC use) have more limited scientific support. Despite the clear efficacy of bisphosphonates to significantly increase bone mass and lower vertebral fracture risk (study designs limited by sample size), bisphosphonates do not prevent osteoporosis complications of GCs, these complications are still of concern at even low doses of GCs.

Another less common bone complication of GCs is osteonecrosis (ON). Although ON may have a similar pathogenesis to that of GC induced osteoporosis, it is very unusual among patients treated with lower doses, such as in RA. Posterior subcapsular cataracts, ubiquitous with prolonged GC treatment, is available to prevent bone disease, cataracts are a major reason for questioning their role in RA management. The advent of effective and safe prevention for GC induced osteoporosis has partially ameliorated this problem. The ACR and a number of other specialty based consensus groups have issued guidelines or position statements advocating a much more aggressive approach to GC induced osteoporosis prevention.

In addition to periodic bone mass measurement, American, Canadian, and Australian guidelines also advocate the aggressive use of aminobisphosphonate drugs such as alendronate or risedronate. Although the indications for the use of bisphosphonate vary based on these different guidelines, patients expected to require prolonged supra-physiological GC doses, those with existing low bone mass (T score < −1.0 in some and less than −1.5 in other guidelines), and postmenopausal women are high risk groups that should receive bisphosphonates sooner rather than later. Other therapeutic options such as calcitonin, oestrogen, testosterone, and possibly, thiazide diuretics (early in the course of GC use) have more limited scientific support. Despite the clear efficacy of bisphosphonates to significantly increase bone mass and lower vertebral fracture risk (study designs limited by sample size), bisphosphonates do not prevent osteoporosis complications of GCs, these complications are still of concern at even low doses of GCs.

Another less common bone complication of GCs is osteonecrosis (ON). Although ON may have a similar pathogenesis to that of GC induced osteoporosis, it is very unusual among patients treated with lower doses, such as in RA. An incidence of ON of <3% was seen at replacement doses and clinically significant ON is seldom reported in patients with RA receiving GC doses below 20 mg/day.

**Gastrointestinal**

Gastrointestinal (GI) AEs of GCs alone are less severe than those seen when non-selective NSAIDs are used. However, when GCs are used in combination with NSAIDs, a synergistic increased risk of GI AEs is observed. In a Medicare database 1400 patients with different inflammatory diseases receiving GC treatment were evaluated: the relative risk of a peptic ulcer or GI bleed was 2.0, but multivariate analysis showed that concomitant use of NSAIDs explained this increased risk, indicating that GCs alone have no increased risk for GI events. In an observational study of 566 patients with RA using steroids (mean duration of use 5.1 years; mean prednisone dose 6.84 mg/day) compared with 253 controls followed up over slightly more than eight years, even low dose prednisone (<5.0 mg/day) was associated with an increased risk of GI ulcerations, with an OR of 1.8 after a mean of 1.5 years of use. This OR increased slightly, up to an OR of 2.1 when GCs were used for more than five years.

**Eye**

Similar to bone disease, cataracts are most typically associated with GC treatment. Biochemically, GC-lysine adducts causing lens particles to form, and inhibition of the sodium-potassium pump increasing the water content of the lens may explain this complication. Although there have been few comprehensive analyses of this risk, posterior subcapsular cataracts may develop in as few as two years on as little as 5 mg/day of prednisone. Of interest, a population based study has also detected a >2.5-fold increased risk of cortical cataracts in GC users compared with non-users.

Inhaled GCs have been associated with increased risk of cataracts, emphasising a potential effect with even very low doses. Overall, limited data on glucocorticoids and cataracts seem to support the association of GCs and cataracts, but these data also highlight the need for more research into this toxicity.

**Cardiovascular**

Although acute hypertension and lipoprotein perturbations with GCs may ultimately result in a higher risk of cardiovascular disease, investigation into this topic is particularly confounded by RA disease activity. An association of RA with a higher risk of cardiovascular disease may relate to a direct deleterious impact of prolonged inflammation on cardiovascular disease. Because anti-inflammatory agents may lower the risk of cardiovascular disease, long term data are needed to determine whether a GC effect on atherosclerotic disease is independent of RA. Prior data from retrospective cohorts have attributed GC use to heightened overall mortality, although confounding by indication is problematic in these types of observational studies. Recent data from cohorts show that RA disease activity alters the blood lipid profile unfavourably, and treatment (including GC treatment) can reverse these changes.

**Glucose metabolism**

It takes only a few weeks before hyperglycaemia can occur when using GCs and there is both a dose-response and inverse duration effect for this end point. At doses of 1–7.9 mg prednisone daily, the OR for hyperglycaemia is 1.8; this rises progressively to an OR of 7 when the dose of prednisone is 25 mg daily or more. The OR of requiring treatment for hyperglycaemia is 1.7 during the first 45 days of corticosteroid use, falls to 1.3 between 46 and 90 days, and is merely 1.1 beyond that point.
caemia was found early in GC use in this study, probably because serum glucose was monitored. The development of overt diabetes in patients using low dose GCs is rare.

Infections
In an American evaluation of 566 patients with RA receiving GCs, a 22.4% incidence of infections versus 13% in the controls was observed. The OR for an infection was 1.72 when steroids were used for six months or longer. This result, however, contrasts with the results from a review on infections complications in patients taking GCs. In five studies quoted in the review, there was no increase in infection rate among rheumatic patients given up to 8 mg GCs daily, although the duration of use of the steroids in those studies was not delineated. Another review stated that GC doses ≥10 mg daily (total dose >700 mg) for at least 3–4 weeks were needed before there was an increased incidence of infection. Infectious complications are badly needed in GC users, although relatively insignificantly for patients receiving low dose GCs for RA.

HPA axis
There is little doubt that higher doses of prednisone over long periods can cause HPA axis suppression and many published reports attest to this effect. On the other hand, the best data relating to very low doses of prednisone come from a meta-analysis comparing the effects of intranasal steroid preparations, which used oral prednisone as a comparator. In an analysis of 13 studies and using 8 00 am serum cortisol as a measure of HPA suppression, it appears that doses <8 mg/day prednisolone (the exact dose is hard to discern from the figure) will suppress 8 00 am cortisol. These data show that low doses of GCs, in the range of the doses often used when treating RA, can regularly cause HPA suppression, although the duration of such treatment required for such an effect to occur is not explicitly defined. To make these data more difficult to interpret, it has been suggested that RA itself has an influence on the HPA axis.

Mental functioning
The doses of prednisone used to treat RA have not usually been associated with steroid psychosis, so this aspect of the side effects of GC in early RA will not be considered further here. However, GCs do seem to have an effect on neuronal death. When GCs are used, translocation of pre-existing glucose cell surface receptors to the intracellular environment seems to occur, resulting in 25–30% inhibition of glucose transport into cells. This accelerates the usual decline in ATP concentrations after ischaemia or hypoglycaemia. This, in turn, decreases the ability to inhibit neuronal insults. This theoretical construct has been carried into a study of normal volunteers given 10 mg oral hydrocortisone in a single blind study. Hippocampal dependent functions such as declarative memory and spatial thinking, as well as non-hippocampal dependent measures such as procedural thinking were tested. The hippocampal dependent functions were found to be impaired. In another test of mental functioning, paired association word recall and consolidation of verbal learning (hippocampal dependent functions) were impaired at the time of hydrocortisone infusions and four days later. These experiments in normal volunteers were later tested in patients with RA who had been receiving GCs for more than one year and compared with the results for controls. Once again, hippocampal functioning (recall of explicit facts) was impaired, while non-hippocampal functioning (procedural memory) was not.

Toxicity summary
An increasing number of clinical trials comparing GC users with non-users inform us about the short and moderate term AEs in GC users. There are credible data that even low dose GCs given for weeks to months can have significant toxicity in numerous areas, including GI ulcerations and bleeding when given together with NSAIDs, an increased incidence of infections, an increased incidence of hyperglycaemia, a predisposition to glaucoma, suppression of the HPA axis, abnormalities in recall and mental functioning, and skin ecchymoses and thinning. Despite this increasing knowledge, longer term data are badly needed to assess the impact of this most commonly used treatment. Bone loss and cataracts are the complications most well validated, whereas other long term AEs need further investigation. Despite the fact that GCs improve functional status and reduce radiographic erosions, it is imperative that we place their long term side effects into the therapeutic equation in order to determine their appropriate place in our treatment armamentarium.

CONCLUSION
There is thus clear evidence that GCs improve physical function and reduce progression of joint damage in the treatment of RA. However, it cannot be emphasised enough that the cautious use of GCs in patients with longstanding RA should be weighed and balanced for the individual patient. A take home message might be: “A little GC, like a glass of wine, may benefit many (some –(sic) people, whereas a high dose of GC, like a bottle of wine is harmful to all”. In both cases long term intake might be harmful.


References


McIntosh LJ, Sapolsky RM. Glucocorticoids may enhance oxygen radical-mediated neurotoxicity. Neurotoxicology 1996;17:873–82.


Glucocorticoids in the treatment of early and late RA

J W J Bijlsma, M Boers, K G Saag and D E Furst

Ann Rheum Dis 2003 62: 1033-1037
doi: 10.1136/ard.62.11.1033

Updated information and services can be found at:
http://ard.bmj.com/content/62/11/1033

These include:

References
This article cites 43 articles, 7 of which you can access for free at:
http://ard.bmj.com/content/62/11/1033#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Biological agents (545)
- Drugs: musculoskeletal and joint diseases (700)
- Inflammation (1251)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/